Author:
Larouche Miriam,Khoury Etienne,Brisson Diane,Gaudet Daniel
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine
Reference73 articles.
1. Ginsberg HN, Packard CJ, Chapman MJ, Boren J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791–806. This expert consensus paper highlights the importance of TRL in cardiovascular risk management and facilitates the classification of hyperTG.
2. Brunzell JD, Deeb SS. Familial lipoprotein lipase deficiency, Apo C-II deficiency, and hepatic lipase deficiency. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA, editors. The Online Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill Education; 2019.
3. Olivecrona G. Role of lipoprotein lipase in lipid metabolism. Curr Opin Lipidol. 2016;27(3):233–41.
4. Rosenson RS, Davidson MH, Hirsh BJ, Kathiresan S, Gaudet D. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014;64(23):2525–40.
5. Gaudet D. 35 - Special Patient Populations: Treatment of Familial Chylomicronemia Syndrome and Sustained Chylomicronemia. In: Ballantyne CM, editor. Clinical Lipidology (Third Edition). New Delhi: Elsevier; 2024. p. 336–44.e2. In this textbook in clinical lipidology, recent data on hyperTG vs cardiovascular risk and emerging therapies are presented (chap 4, 27, 28, and 35 specifically.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献